Jean-Yves Blay
Director/Board Member at INNATE PHARMA
Net worth: 118 $ as of 29/04/2024
Profile
Jean-Yves Blay is currently an Independent Director at Transgene SA since 2022, the General Director at Centre Léon Bérard Lyon et Rhône-Alpes since 2014, and an Independent Member-Supervisory Board at Innate Pharma SA since 2017.
Previously, he served as the President of the European Organisation for Research & Treatment of Cancer from 2009 to 2012 and as the President of UNICANCER from 2019 to 2022.
He also held the position of Secretary-Oncology Commission at Académie Nationale de Médecine FCP.
Dr. Blay obtained his doctorate degree from Université Claude Bernard Lyon 1 in 1994.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
INNATE PHARMA SA CLASS A
0.00% | 30/12/2022 | 50 ( 0.00% ) | 118 $ | 29/04/2024 |
Jean-Yves Blay active positions
| Companies | Position | Start |
|---|---|---|
| INNATE PHARMA | Director/Board Member | 12/12/2017 |
| TRANSGENE | Director/Board Member | 24/05/2022 |
| Centre Léon Bérard Lyon et Rhône-Alpes | Chief Executive Officer | 31/12/2013 |
Former positions of Jean-Yves Blay
| Companies | Position | End |
|---|---|---|
UNICANCER
 UNICANCER Hospital/Nursing ManagementHealth Services UNICANCER is a French hospital network that is dedicated to fighting against cancer. The private company is based in Paris, France. It is the only national hospital federation that is solely focused on oncology. The network comprises of 18 French cancer centers (CLCC) and a private non-profit health establishment. The CLCCs take care of almost 530,000 patients annually. UNICANCER is also a leading academic promoter of clinical trials in oncology in Europe, with 106 active clinical trials promoted and nearly 7,600 patients included. | President | 31/12/2021 |
| European Organisation for Research & Treatment of Cancer | President | 31/12/2011 |
| Académie Nationale de Médecine FCP | Corporate Officer/Principal | - |
Training of Jean-Yves Blay
| Université Claude Bernard Lyon 1 | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| TRANSGENE | Health Technology |
| INNATE PHARMA | Health Technology |
| Private companies | 4 |
|---|---|
| European Organisation for Research & Treatment of Cancer | |
| Académie Nationale de Médecine FCP | Commercial Services |
UNICANCER
UNICANCER Hospital/Nursing ManagementHealth Services UNICANCER is a French hospital network that is dedicated to fighting against cancer. The private company is based in Paris, France. It is the only national hospital federation that is solely focused on oncology. The network comprises of 18 French cancer centers (CLCC) and a private non-profit health establishment. The CLCCs take care of almost 530,000 patients annually. UNICANCER is also a leading academic promoter of clinical trials in oncology in Europe, with 106 active clinical trials promoted and nearly 7,600 patients included. | Health Services |
| Centre Léon Bérard Lyon et Rhône-Alpes |
- Stock Market
- Insiders
- Jean-Yves Blay
